Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 10...
PLYMOUTH MEETING, Pa., March 21, 2019 /PRNewswire-AsiaNet/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases ( https://c...
Authors: LATEST ASIANET NEWS RELEASES